Contributions
Abstract: EP1593
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background: Among adipokines, adiponectin plays important roles in the regulation of energy homeostasis and insulin sensitivity, enough to be considered a marker for obesity and related diseases as type II diabetes. Moreover, an immunomodulatory action in several sistemic inflammatory disorders has been demostrated. Adiponectin is produced as a monomer that circulates in serum as different oligomers (LMW, MMW, HMW). Few studies analyzed the adiponectin role in a neuroinflammatory disorders as Multiple Sclerosis (MS) with controversial results. In this study, we analyzed serum adiponectin levels in MS patients and investigated the potential relationships with disease features.
Methods: 99 unrelated MS patients, diagnosed according to Mc Donald Criteria, from University of Campania “Luigi Vanvitelli”, and 87 age-and sex-matched controls were recruited. Anthropometric and biochemical features of MS patients and controls were evaluated and compared. In serum, adiponectin levels were measured by ELISA. Adiponectin oligomeric profile was characterized by Western blot.
Results: Serum adiponectin levels analyzed by ELISA assay were higher in MS patients compared to matched controls (12,18 vs 10,02 µg/ml) (p< 0,001). A negative correlation was found between adiponectin levels and BMI in controls while a positive correlation was present in patients. No difference in adiponectin was found between active/no active patients and between forms of disease. Western blotting analysis performed on serum demonstrated that the HMW adiponectin oligomers are increased in MS patients.
Discussion and conclusions: Our study demonstrated a strong modulation of adiponectin and its HMW oligomers in MS. The positive correlation of adiponectin with BMI in MS patients suggests that adiponectin plays a role in the regulation of neuroinflammatory conditions as MS, probably acting towards pro-inflammatory pathways at the basis of MS. Further studies are required to better understand the biological role of adiponectin and its possible usefulness as a biomarker of MS.
Disclosure: Elisabetta Signoriello has received personal compensation for activities with Biogen Idec, Roche, Merck Serono, Novartis as a consultant; has received support for travelling from Biogen Idec, Merck Serono, Novartis, Teva, Roche, Genzyme
Giacomo Lus has received personal compensation for activities with Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis Pharmaceuticals, Teva neuroscience as a consultant and speaker; has received research support from Biogen Idec, Merck Serono, and Novartis
Marcella Coletta, Fabiana Rossi, Sara Casertano, Aurora Daniele, Ersilia Nigro, Maria Ludovica Monaco, Olga Scudiero, Rita Polito have no disclosures
Abstract: EP1593
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background: Among adipokines, adiponectin plays important roles in the regulation of energy homeostasis and insulin sensitivity, enough to be considered a marker for obesity and related diseases as type II diabetes. Moreover, an immunomodulatory action in several sistemic inflammatory disorders has been demostrated. Adiponectin is produced as a monomer that circulates in serum as different oligomers (LMW, MMW, HMW). Few studies analyzed the adiponectin role in a neuroinflammatory disorders as Multiple Sclerosis (MS) with controversial results. In this study, we analyzed serum adiponectin levels in MS patients and investigated the potential relationships with disease features.
Methods: 99 unrelated MS patients, diagnosed according to Mc Donald Criteria, from University of Campania “Luigi Vanvitelli”, and 87 age-and sex-matched controls were recruited. Anthropometric and biochemical features of MS patients and controls were evaluated and compared. In serum, adiponectin levels were measured by ELISA. Adiponectin oligomeric profile was characterized by Western blot.
Results: Serum adiponectin levels analyzed by ELISA assay were higher in MS patients compared to matched controls (12,18 vs 10,02 µg/ml) (p< 0,001). A negative correlation was found between adiponectin levels and BMI in controls while a positive correlation was present in patients. No difference in adiponectin was found between active/no active patients and between forms of disease. Western blotting analysis performed on serum demonstrated that the HMW adiponectin oligomers are increased in MS patients.
Discussion and conclusions: Our study demonstrated a strong modulation of adiponectin and its HMW oligomers in MS. The positive correlation of adiponectin with BMI in MS patients suggests that adiponectin plays a role in the regulation of neuroinflammatory conditions as MS, probably acting towards pro-inflammatory pathways at the basis of MS. Further studies are required to better understand the biological role of adiponectin and its possible usefulness as a biomarker of MS.
Disclosure: Elisabetta Signoriello has received personal compensation for activities with Biogen Idec, Roche, Merck Serono, Novartis as a consultant; has received support for travelling from Biogen Idec, Merck Serono, Novartis, Teva, Roche, Genzyme
Giacomo Lus has received personal compensation for activities with Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis Pharmaceuticals, Teva neuroscience as a consultant and speaker; has received research support from Biogen Idec, Merck Serono, and Novartis
Marcella Coletta, Fabiana Rossi, Sara Casertano, Aurora Daniele, Ersilia Nigro, Maria Ludovica Monaco, Olga Scudiero, Rita Polito have no disclosures